What's new? Log in Free sign up

Lixte Biotechnology (LIXT)

Company Profile

Company profile

Ticker

LIXT, LIXTW

Exchange

Website

CEO

Mr. Bastiaan van der Baan M.Sc.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

SRKP 7 INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Lixte Biotechnology, Inc. ...

LIXT stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

LIXTE Adds Northwestern University’s Lurie Cancer Center

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Prospectus supplement for primary offering

Registration withdrawal request

Prospectus supplement for primary offering

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers

Latest ownership filings

View all

Orca Capital AG

INTRACOASTAL CAPITAL, LLC

Orca Capital AG

Stephen J. Forman

Stephen J. Forman

Financial summary

Financial statements Chart LIXT financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

LIXT institutional ownership history Ownership history

15.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	12	0	NEW
Opened positions	12	0	NEW
Closed positions	0	1	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	526.41 mm	0.00	NEW
Total shares	347.44 k	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Tiaa Trust, National Association	101.83 k	$206.69 mm	NEW
HighTower Advisors	99.43 k	$201.82 mm	NEW
FNY Investment Advisers	39.22 k	$82.00 k	NEW
Citadel Advisors	27.33 k	$793.00 k	NEW
Ethos Financial	24.81 k	$50.35 mm	NEW
Clear Street	22.55 k	$1.00 k	NEW
Geode Capital Management	16.87 k	$35.42 mm	NEW
Atlas Legacy Advisors	12.71 k	$25.79 mm	NEW
UBS UBS	1.96 k	$3.97 mm	NEW
Tower Research Capital	681.00	$1.38 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Tiaa Trust, National Association	101.83 k	+101.83 k	NEW
HighTower Advisors	99.43 k	+99.43 k	NEW
FNY Investment Advisers	39.22 k	+39.22 k	NEW
Citadel Advisors	27.33 k	+27.33 k	NEW
Ethos Financial	24.81 k	+24.81 k	NEW
Clear Street	22.55 k	+22.55 k	NEW
Geode Capital Management	16.87 k	+16.87 k	NEW
Atlas Legacy Advisors	12.71 k	+12.71 k	NEW
UBS UBS	1.96 k	+1.96 k	NEW
Tower Research Capital	681.00	+681.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LIXT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jan 25	Rene Bernards	Options to Purchase Common Stock Common	Grant	Acquire A	No	No	2.33	4,166	9.71 k	4,166
20 Jan 25	Regina Brown	Options to Purchase Common Stock Common	Grant	Acquire A	No	No	2.33	4,924	11.47 k	4,924
20 Jan 25	Yun Yen	Options to Purchase Common Stock Common	Grant	Acquire A	No	No	2.33	4,545	10.59 k	4,545
20 Jan 25	Stephen J. Forman	Options to Purchase Common Stock Common	Grant	Acquire A	No	No	2.33	3,030	7.06 k	3,030
30 Sep 24	Rene Bernards	Options to Purchase Common Stock Common	Grant	Acquire A	No	No	1.3	5,304	6.90 k	5,304

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Press releases

From Benzinga Pro

New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form

-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE"

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced the closing of its previously

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that it has entered into

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.